N/A N=49 Clinical Evaluation of a Multifocal Contact Lens on Symptomatic Patients
Presbyopia
Primary: Subject Reported Overall Vision Quality Using (CLUE)TM Questionnaire — 41.0; 39.0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=75 A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
Solid Tumor
Primary: The Difference in the Change From Baseline (Predose on Day 1) in QTc Intervals Trabectedin Relative to Placebo at 24 Hour Post Dose by Fridericia Correction — 3.6; -6.2…
N/A N=96 A Study of the Use of Chartis System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR)
Emphysema
Primary: Lung Volume Change — 56; 6 percent decrease in lung volume
N/A N=40 Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)
Urinary Incontinence
Primary: Time to Continence — 95 Days to Continence
Phase 2 N=40 Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer
Squamous Cell Carcinoma
Primary: Response Rate to Induction Chemotherapy Prior to Definitive Therapy (Surgery or Radiation) — 32 participants
Phase 3 N=20 Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV
Diabetes · Insulin Resistance
Primary: CD4+ T-cell Count — 602; 648; 689; 750 cells/µL — p=>0.05
Phase 3 N=2,954 Novartis Vaccine and Diagnostics Carriage Trial
N. Meningitidis Carriage
Primary: Percentages of Subjects With Carriage of Virulent Sequence Types (ST) of Neisseria Meningitidis Group B, One Month After Completion of rMenB+OMV NZ Vaccination — 8; 7…
Phase 1 N=48 The Effect of Palatal Brushing on Denture Stomatitis
Denture Stomatitis
Primary: Palatal Inflammation — 3; 3; 2.5; 2 units on a scale — p=<0.0001
Phase 3 N=200 Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)
Osteoporosis
Primary: Number of Participants With Serum 25-hydroxyvitamin D >=50 ng/mL at Week 26 — 1; 3; 1; 5 Participants
Phase 3 N=3,883 E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events
Secondary Hyperparathyroidism · Chronic Kidney Disease
Primary: Time to Primary Composite Endpoint (All-cause Mortality, Myocardial Infarction, Hospitalization for Unstable Angina, Heart Failure or Peripheral Vascular Event) — 55.0…
Phase 2 N=71 CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Recurrent Mantle Cell Lymphoma
Primary: Overall Response Rate (Complete and Partial Responses) as Defined by the International Workshop Criteria — 62.5; 52.4 percentage of patients
N/A N=56 Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data
Glaucoma
Primary: 6-month Change in Ophthalmic Artery (OA) Peak Systolic Velocity (PSV) — 2.32; -.30 cm/sec — p=.6261
Phase 2 N=22 Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma · Recurrent Metastatic Squamous Neck Cancer With Occult Primary · Recurrent Squamous Cell Carcinoma of the Hypopharynx
Primary: Objective Tumor Response Rate (Complete Response [CR] and Partial Response [PR]) Using RECIST Criteria — 6.7; 0 percentage of participants
Phase 1 N=41 A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot
Schizophrenia
Primary: Number of Participants With Adverse Events as a Measure of Safety — 11; 11; 6 Participants
N/A N=2,196 Study of Lipid Control in Hyperlipidemic Participants (MK-0653-179)
Dyslipidemia
Primary: Percentage of Participants Achieving Target Lipid Values — 46.8 Percentage of participants